Cash-rich pharma is dropping any pretence they are buying cash-strapped biotech for access to innovative technology. What it wants is products. Let’s hope it doesn’t suffocate the feedstock of innovation in the process.
Turmoil in the financial markets is having a disproportionate impact on biotech – and coupled with extra caution from regulators, is threatening innovation.